Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
July 9, 2019Pivotal study will test novel, oral antidepressant in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation & Behavior following initial stabilization with ketamineNeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has initiated a pivotal Phase 2b/3 study for NRX-101...
-
June 3, 2019First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation
NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, will present phase 2 efficacy results from its...
-
May 30, 2019Findings suggest potential efficacy for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine.
NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B...
-
December 13, 2018Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, announced results from...
-
November 13, 2018First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted...
Click here to view our corporate presentation or on the image below
 |
